“GenoSplice annonce de nouvelles pistes menant à l’identification de biomarqueurs pronostiques dans le cancer du sein à partir d’évènements d’épissage” You can acces this press release in french in pdf format.
Frédéric Lemoine will participate in the developments of GenoSplice, in particular regarding the analysis of high-throughput sequencing data.
We applied our EASANA® platform to analyze the splicing factor expression and transcriptome among 11 normal human tissues using the Affymetrix Exon Arrays (collaboration with INSERM). Article “Splicing factor and exon profiling across human tissues.” de la Grange P, Gratadou L, Delord M, Dutertre M, Auboeuf D. Nucleic Acids Res. Read more…
We applied our EASANA® platform to identify regulated exons between mammary gland primary tumors with different metastatic property. Expression of the subsequent validated splicing variants was then correlated with prognosis of breast cancer patients through restrospective study (collaboration with INSERM, CNRS and the Curie Institute). Article “Exon-based clustering of murine Read more…
The Scientipole Initiative support young and innovative french companies.
Les puces à épissage alternatif : de l’ARN au diagnostic This article from “La Gazette du Laboratoire” is available in pdf format.
This financial support from Oseo will be dedicated to develop analysis system for new transcriptomic techniques, including the last Junction Arrays.
Les puces à épissage alternatif : de l’ARN au diagnostic This press release is available in french in pdf format.
GenoSplice will present its services, products and last research results during an <a href=”http://www.istem.eu/ewb_pages/i/internal-seminar-865.php”>”I-STEM external seminar”.